In addition and according to our in silico observations that need further confirmation, it could be postulated that SS risk variants control DNA-protein binding leading to the regulation of cell-specific promoters (Pol II, NF-κB, STATs), enhancers (NF-κB), and insulators (CTCF). This evidence concerns the gene NFKB1 and synovial sarcoma.